A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study

Trial Profile

A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Aramchol (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms ARREST
  • Sponsors Galmed Medical Research
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Jan 2017 According to a Galmed Pharmaceuticals media release, results are anticipated to be announced in second quarter of 2018.
    • 09 Jan 2017 Status changed from recruiting to active, no longer recruiting., as reported in a Galmed Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top